enVVeno Medical Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Duhay Francis, was filed 03 Jan 2025.
Who traded when
BuySaleSince the insiders bought
- -89.2%Entry US$120.40 · Close at T+365 US$13.06
- -88.9%Entry US$117.60 · Close at T+365 US$13.06
- -89.5%Entry US$110.25 · Close at T+365 US$11.59
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 11 shares@ US$11.210.0023% mcap0.0% of flowCommon StockSEC:0001493152-26-042629:0
- 11 shares@ US$11.18180.0023% mcap0.0% of flowCOMMONSEC144:0001949846-26-000579
- 140 shares@ US$10.30710.021% mcap0.4% of flowCOMMONSEC144:0001949846-26-000375
- 140 shares@ US$11.52240.5% of flowCommon StockSEC:0001493152-26-010047:0
- 4,900 shares@ US$0.35560.5% of flowCommon StockSEC:0001493152-25-027510:0
- 4,900 shares@ US$0.831.2% of flowCommon StockSEC:0001493152-25-013837:0
- 81,433 shares@ US$3.0781.5% of flowCommon StockSEC:0001493152-25-000160:0Canonical exit: 31 Mar 2025 (T+90)
- 3,500 shares@ US$2.94100.0% of flowCommon StockSEC:0001493152-25-000058:0Canonical exit: 31 Mar 2025 (T+90)
- 5,400 shares@ US$2.9080.4% of flowCommon StockSEC:0001493152-24-052112:0Canonical exit: 24 Mar 2025 (T+90)
- 9,620 shares@ US$2.53100.0% of flowCommon StockSEC:0001493152-24-051172:0Canonical exit: 19 Mar 2025 (T+90)
- 12,000 shares@ US$2.5545.2% of flowCommon StockSEC:0001493152-24-050865:0Canonical exit: 19 Mar 2025 (T+90)
- 8,334 shares@ US$6.2263.4% of flowCommon StockSEC:0001493152-24-010168:1
- 8,334 shares@ US$3.59100.0% of flowCommon StockSEC:0001493152-24-010168:0
- 1,041 sharesCommon StockSEC:0001493152-22-026070:0
- 1,041 sharesCommon StockSEC:0001493152-22-026071:0
- 7,751 shares@ US$6.1415.9% of flowCommon StockSEC:0001493152-22-023461:0Canonical exit: 14 Nov 2022 (T+90)
- 1,000 shares@ US$3.850.056% mcap19.6% of flowCommon StockSEC:0001493152-22-018361:0Canonical exit: 28 Sept 2022 (T+90)
- 2,500 shares@ US$3.800.14% mcap13.7% of flowCommon StockSEC:0001493152-22-017957:0Canonical exit: 25 Sept 2022 (T+90)
- 200,000 sharesCommon StockSEC:0001493152-21-030335:0
- 50,000 sharesCommon StockSEC:0001493152-21-030331:0
- 100,000 sharesCommon StockSEC:0001493152-21-030333:0
- 2,000 shares@ US$7.4320.0% of flowCommon StockSEC:0001493152-21-029430:0Canonical exit: 17 Feb 2022 (T+90)
- 388 sharesCommon StockSEC:0001493152-21-029234:0
- 2,000 shares@ US$7.8721.2% of flowCommon StockSEC:0001493152-21-029229:0Canonical exit: 14 Feb 2022 (T+90)
- 1,042 sharesCommon StockSEC:0001493152-21-022863:0
25 of 73 declarations
About enVVeno Medical Corp
On December 31, 2024, director Francis Duhay bought EUR 240,242 of enVVeno Medical Corp shares, the largest purchase on record, at the close of a window running December 19 to December 31, 2024 in which five insiders bought EUR 318,259 in all. Sales weigh more over the whole record: 36 sales worth EUR 1.22 million (median EUR 19,898), against 17 purchases worth EUR 530,716 (median EUR 13,848).
The three largest sales are all by Biodyne Holding, S.A.: EUR 406,886 on June 7, 2019, EUR 86,711 on June 17, 2020 and EUR 64,883 on June 2, 2020. This holder of more than 10% of the securities is the top filer, with 32 filings, 31 of them sales. Robert Andrew Berman, Chief Executive Officer, has 7 purchases out of 8 filings.
Read moreShow less
A US healthcare and pharma company listed on Nasdaq, enVVeno has a known market capitalisation of USD 5,350,160, and its 12 filers hold 8.2% of the capital. The record holds 73 filings published from November 29, 2018 to September 14, 2026, peaking at 35 in 2020. 5 filings fall in the last twelve months, 3 of them sales. For 17 purchases a 90-day result is stored: a median of minus 5.1%, with 47% of results positive. These are recorded past results, not a forecast.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
